Copertina

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors

Multiple myeloma (MM) is still a fatal plasma cell cancer. Novel compounds are currently clinically tested as a single agent in relapsing patients, but in best cases with partial response of a fraction of patients, emphasising the need to design tools predicting drug efficacy. Histone deacetylase in...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Moreaux, Jérôme (Autore) , Reme, T. (Autore) , Leonard, W. (Autore) , Veyrune, J.-L. (Autore) , Requirand, G. (Autore) , Goldschmidt, Hartmut (Autore) , Hose, Dirk (Autore) , Klein, B. (Autore)
Natura: Article (Journal)
Lingua:inglese
Pubblicazione: 18 July 2013
In: British journal of cancer
Year: 2013, Volume: 109, Fascicolo: 3, Pages: 676-685
ISSN:1532-1827
DOI:10.1038/bjc.2013.392
Accesso online:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/bjc.2013.392
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/bjc2013392
Testo
Note sull'autore:J. Moreaux, T. Reme, W. Leonard, J.-L. Veyrune, G. Requirand, H. Goldschmidt, D. Hose and B. Klein
Descrizione
Riassunto:Multiple myeloma (MM) is still a fatal plasma cell cancer. Novel compounds are currently clinically tested as a single agent in relapsing patients, but in best cases with partial response of a fraction of patients, emphasising the need to design tools predicting drug efficacy. Histone deacetylase inhibitors (HDACi) are anticancer agents targeting epigenetic regulation of gene expression and are in clinical development in MM.
Descrizione del documento:Gesehen am 07.06.2021
Descrizione fisica:Online Resource
ISSN:1532-1827
DOI:10.1038/bjc.2013.392

Documenti analoghi